New and Updated Clinical Dengue Vaccine Trials

Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia

Aug 21, 2019 | 18:00 pm

Condition: DengueIntervention: Diagnostic Test: Dengue calculatorSponsors: Lyda Osorio; COMFANDI CAJA DE COMPENSACION DEL VALLE DEL CAUCA; SISTEMA GENERAL DE REGALIAS CASANARE, SANTANDER VALLE DEL CAUCA; RED AEDESCompleted

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

May 23, 2019 | 18:00 pm

Condition: DengueIntervention: Biological: CYD-TDVSponsors: Albert B. Sabin Vaccine Institute; Pan American Health Organization; State of Parana/Health Department of Parana; Ministry of Health of Brazil; Centro de Estudos Augusto Leopoldo Ayrosa GalvãoRecruiting

Expansion of a Dengue-1 Live Virus Human Challenge

Mar 11, 2019 | 17:00 pm

Condition: DengueIntervention: Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)Sponsors: State University of New York - Upstate Medical University; Janssen Pharmaceutica N.V., Belgium; U.S. Army Medical Research and Development CommandRecruiting

Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquitoes

Jan 10, 2019 | 18:00 pm

Condition: DengueIntervention: Other: GOS trap and dengue NS1 antigen kitSponsors: Jonathan Liew Wee Kent; Petaling Jaya City Council, Malaysia; Selangor State Health Department, MalaysiaRecruiting

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Dec 11, 2018 | 18:00 pm

Condition: Dengue FeverIntervention: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Sponsor: TakedaActive, not recruiting

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Nov 19, 2018 | 18:00 pm

Condition: Dengue FeverIntervention: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Sponsor: TakedaRecruiting

Pilot Study to Detect DENGUE Virus in Sperm

Aug 2, 2018 | 18:00 pm

Condition: DengueIntervention: Biological: blood, urine and semen sampleSponsor: University Hospital, ToulouseCompleted

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Nov 14, 2017 | 18:00 pm

Condition: DengueInterventions: Biological: Tetravalent Dengue Vaccine (TDV); Biological: PlaceboSponsor: TakedaCompleted

Applying Wolbachia to Eliminate Dengue

Feb 16, 2017 | 18:00 pm

Conditions: Dengue; Zika Virus Infection; Chikungunya FeverInterventions: Biological: Wolbachia-infected Aedes aegypti mosquitoes; Other: standard practice dengue controlSponsors: Gadjah Mada University; Monash University; The Tahija FoundationRecruiting

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dec 14, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine; Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedSponsor: Sanofi Pasteur, a Sanofi CompanyActive, not recruiting

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Jul 11, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Haemorrhagic FeverIntervention: Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Jul 6, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine (5 dose formulation); Biological: Placebo, NaCl 0.9%Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Apr 18, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic Fever; Human Immunodeficiency VirusInterventions: Biological: CYD Dengue Vaccine; Biological: Placebo (NaCl 0.9%) vaccine groupSponsor: Sanofi Pasteur, a Sanofi CompanyNot yet recruiting

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dec 11, 2015 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine; Biological: Placebo (NaCl 0.9%)Sponsor: Sanofi Pasteur, a Sanofi CompanyActive, not recruiting

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dec 8, 2015 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine (5-dose formulation); Biological: Placebo, NaCl 0.9%Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

May 5, 2015 | 18:00 pm

Condition: DengueInterventions: Biological: Recombinant live attenuated trivalent dengue vaccine; Biological: Placebo; Biological: rDEN2Δ30-7169 vaccineSponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Apr 2, 2015 | 18:00 pm

Condition: DengueInterventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine; Other: PlaceboSponsor: Butantan InstituteRecruiting

Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain

Feb 26, 2015 | 18:00 pm

Condition: DengueIntervention: Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)Sponsors: U.S. Army Medical Research and Development Command; State University of New York - Upstate Medical UniversityCompleted

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Jun 16, 2011 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic Fever; DengueInterventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Biological: Placebo: (NaCl) 0.9% solutionSponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Jun 14, 2011 | 18:00 pm

Conditions: Dengue; Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Biological: Placebo: Sodium chloride (NaCl) 0.9%Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Main Menu

Login Form

Related Links